Why do the biotech ventures mange to have such promising drug candidates while pharmaceutical R&D is facing a drug deficit?
Sylvia M. Findlay
Advertisement
Sylvia Findlay is Pharmaceuticals and Biotechnology Industry Analyst at Frost & Sullivan.
Articles by Sylvia M. Findlay
FDA has tightened up the approval of new drugs, ensuring careful scrutiny of clinical data and stringent scanning to analyse the probable side-effects of a new drug
Advertisement
Latest Updated Articles
- New age therapies
Published: December 1st 2006 | Updated:
Spotlight: Market analysis Beating the blockbuster bluesPublished: January 1st 2006 | Updated:
Advertisement
Advertisement
